The RESOLVD Pilot Study was a trial of combination neurohormonal blockade using an angiotensin II antagonist (candesartan), an angiotensin-converting enzyme inhibitor (enalapril) and a beta-blocker (metoprolol) in patients with congestive heart failure (CHF).

End points:

Change in 6MWD, EF, ventricular volumes, neurohormone levels, QOL, and NYHA-FC at weeks 17 or 18 and 43. Tolerance and adverse and clinical events were documented, with serious adverse events reviewed centrally.

Co-Principal Investigator on the RESOLVD study was Robert McKelvie, now Professor of Medicine (Cardiology) at Western University in London, Ontario.

Study Type

Interventional - Drug

Study Design

Randomized, two-stage trial consisting of a three-way comparison (stage I), followed by a 3×2 partial factorial design (stage II).

NO. of Participants


Study Period




Back To Top